Trial Profile
Effects Of Eltrombopag On Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Haemorrhage; Platelet dysfunction; Thrombocytopenia
- Focus Therapeutic Use
- 15 Mar 2019 Status changed from active, no longer recruiting to discontinued.
- 31 Jan 2017 Planned End Date changed from 1 Jun 2013 to 1 Jun 2020.
- 31 Jan 2017 Planned primary completion date changed from 1 Jun 2013 to 1 May 2019.